LakeShore Biopharma (LSB) Competitors $0.83 +0.03 (+3.25%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LSB vs. RPTX, IVVD, GANX, INKT, COEP, MNOV, GNTA, ADVM, CUE, and ALGSShould you be buying LakeShore Biopharma stock or one of its competitors? The main competitors of LakeShore Biopharma include Repare Therapeutics (RPTX), Invivyd (IVVD), Gain Therapeutics (GANX), MiNK Therapeutics (INKT), Coeptis Therapeutics (COEP), MediciNova (MNOV), Genenta Science (GNTA), Adverum Biotechnologies (ADVM), Cue Biopharma (CUE), and Aligos Therapeutics (ALGS). These companies are all part of the "pharmaceutical products" industry. LakeShore Biopharma vs. Its Competitors Repare Therapeutics Invivyd Gain Therapeutics MiNK Therapeutics Coeptis Therapeutics MediciNova Genenta Science Adverum Biotechnologies Cue Biopharma Aligos Therapeutics Repare Therapeutics (NASDAQ:RPTX) and LakeShore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings. Is RPTX or LSB more profitable? LakeShore Biopharma's return on equity of 0.00% beat Repare Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Repare TherapeuticsN/A -78.25% -66.85% LakeShore Biopharma N/A N/A N/A Do institutionals & insiders believe in RPTX or LSB? 85.1% of Repare Therapeutics shares are owned by institutional investors. Comparatively, 52.6% of LakeShore Biopharma shares are owned by institutional investors. 11.5% of Repare Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, RPTX or LSB? Repare Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, LakeShore Biopharma has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Which has stronger valuation & earnings, RPTX or LSB? LakeShore Biopharma has higher revenue and earnings than Repare Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRepare Therapeutics$250K286.97-$84.69M-$2.58-0.65LakeShore Biopharma$614.96M0.03-$13.93MN/AN/A Does the media prefer RPTX or LSB? In the previous week, LakeShore Biopharma had 2 more articles in the media than Repare Therapeutics. MarketBeat recorded 3 mentions for LakeShore Biopharma and 1 mentions for Repare Therapeutics. Repare Therapeutics' average media sentiment score of 1.88 beat LakeShore Biopharma's score of 0.90 indicating that Repare Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Repare Therapeutics Very Positive LakeShore Biopharma Positive Do analysts rate RPTX or LSB? Repare Therapeutics presently has a consensus target price of $4.50, indicating a potential upside of 169.46%. Given Repare Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Repare Therapeutics is more favorable than LakeShore Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Repare Therapeutics 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50LakeShore Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryRepare Therapeutics beats LakeShore Biopharma on 8 of the 13 factors compared between the two stocks. Get LakeShore Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LSB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSB vs. The Competition Export to ExcelMetricLakeShore BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.15M$3.08B$5.76B$9.75BDividend YieldN/A2.26%3.95%4.02%P/E RatioN/A20.9231.4526.39Price / Sales0.03355.43431.57159.28Price / CashN/A44.7137.7559.42Price / Book0.258.0410.566.59Net Income-$13.93M-$53.98M$3.27B$265.83M7 Day Performance-0.36%-0.89%0.60%0.18%1 Month Performance-8.27%5.66%5.42%2.13%1 Year Performance-81.32%9.06%50.36%21.07% LakeShore Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSBLakeShore Biopharma1.1611 of 5 stars$0.83+3.3%N/A-81.9%$17.15M$614.96M0.00773News CoverageRPTXRepare Therapeutics2.8239 of 5 stars$1.61+1.9%$4.50+179.5%-45.0%$67.88M$53.48M-0.62180Positive NewsHigh Trading VolumeIVVDInvivyd4.0365 of 5 stars$1.03+84.0%$3.18+209.1%+10.0%$67.24M$46.21M-1.12100Analyst ForecastGap UpHigh Trading VolumeGANXGain Therapeutics2.1696 of 5 stars$1.92+4.3%$7.80+306.3%+41.4%$66.14M$50K-3.0520News CoverageAnalyst RevisionINKTMiNK Therapeutics2.736 of 5 stars$15.15+4.0%$37.50+147.5%+86.4%$65.90MN/A-5.2630COEPCoeptis Therapeutics0.657 of 5 stars$13.21-3.2%N/A+225.3%$65.82M$263.56K-2.282News CoveragePositive NewsGap UpMNOVMediciNova2.2091 of 5 stars$1.36+3.0%$7.00+414.7%-2.2%$64.74M$1M-5.4410Analyst ForecastGap UpGNTAGenenta Science2.3356 of 5 stars$3.52+0.9%$25.00+610.2%-6.1%$63.83MN/A0.007News CoverageGap UpADVMAdverum Biotechnologies4.1306 of 5 stars$3.16+4.3%$19.75+525.0%-56.2%$63.48M$1M-0.40190CUECue Biopharma2.5569 of 5 stars$0.84+2.7%N/A+14.5%$62.88M$9.29M-1.5060ALGSAligos Therapeutics4.425 of 5 stars$10.98+7.5%$50.00+355.4%-15.2%$62.81M$3.94M-0.5590Positive News Related Companies and Tools Related Companies Repare Therapeutics Competitors Invivyd Competitors Gain Therapeutics Competitors MiNK Therapeutics Competitors Coeptis Therapeutics Competitors MediciNova Competitors Genenta Science Competitors Adverum Biotechnologies Competitors Cue Biopharma Competitors Aligos Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LSB) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LakeShore Biopharma Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share LakeShore Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.